Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers
Angeline L Wang, Eric Weinlander, Brandon M Metcalf, Neal P Barney, David M Gamm, Sarah M Nehls, Michael C Struck, Angeline L Wang, Eric Weinlander, Brandon M Metcalf, Neal P Barney, David M Gamm, Sarah M Nehls, Michael C Struck
Abstract
Purpose: To report the clinical course of 6 patients with refractory neurotrophic corneal ulcers that were treated with topical insulin drops.
Methods: Retrospective chart review of patients who had neurotrophic corneal ulcers or epithelial defects refractory to standard medical and surgical treatment. Insulin drops, prepared by mixing regular insulin in artificial tears with a polyethylene glycol and propylene glycol base at a concentration of 1 unit per milliliter, were prescribed 2 to 3 times daily.
Results: Six patients, aged 2 to 73 years, developed neurotrophic corneal ulcers refractory to a range of medical and surgical treatments, including bandage contact lens, amniotic membrane grafting, and permanent tarsorrhaphy. Each patient was administered topical insulin drops with complete corneal reepithelialization within 7 to 25 days.
Conclusions: Topical insulin may be a simple and effective treatment for refractory neurotrophic corneal ulcers. Further study is required to determine the clinical efficacy and side effect profile of insulin drops.
Conflict of interest statement
Conflicts of Interest
Dr. Michael Struck holds the patent for use of topical insulin to treat corneal epithelial disease. The remaining authors have no conflicts of interest to disclose
Figures
Source: PubMed